Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Lenalidomide-13C5,15N

  Cat. No.:  DC67367   Featured
Chemical Structure
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Lenalidomide-13C5,15N is an isotopically labeled analog of lenalidomide (HY-A0003; CC-5013), a thalidomide-derived molecular glue compound. This orally bioavailable immunomodulator functions through selective cereblon (CRBN) E3 ubiquitin ligase engagement, mediating targeted ubiquitination and proteasomal degradation of lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 complex. The compound demonstrates dual therapeutic activity by both suppressing proliferation of mature B-cell malignancies (including multiple myeloma) and enhancing T-cell immunostimulation through IL-2 induction.
Cas No.:
Chemical Name: Lenalidomide-13C5,15N
Synonyms: CC-5013-13C5,15N
SMILES: O=C1C2=CC=CC(N)=C2C[15N]1[13CH]([13C](N3)=O)[13CH2][13CH2][13C]3=O
Formula: C813C5H13N215NO3
M.Wt: 265.22
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
Cat. No. Product name Field of application
DC60864 D927 (DS11252927) D927 is a molecular glue and promotes glucose uptake in the absence of insulin. D927 also increases the affinity of RAS binding to PI3Kα by ~500-fold. In vivo, D927 mimicks the effects of insulin and rapidly lowers blood glucose concentrations.
DC60863 D223 (DS02312223) D223 is a molecular glue and promotes glucose uptake in the absence of insulin. D223 also increases the affinity of RAS binding to PI3Kα by ~500-fold.
DC60858 LC-04-045 LC-04-045 is a leading NEK7 molecular glue degrader with DC50 of 7 nM and Dmax of 90 % in MOLT-4 cells. LC-04-045 displays high selectivity for NEK7 across the proteome.
DC60852 PVTX-405 PVTX-405 is a potent, effective, highly selective, and orally efficacious IKZF2 molecular glue degrader with DC50 of  0.7 nM. PVTX-405 in combination with anti-PD1 or anti-LAG3 significantly increases animal survival compared to anti-PD1 or anti-LAG3 alone.
DC60837 MGD-28 MGD-28 is a potent molecular glue degrader that demonstrates significant in vitro efficacy against various hematological cancer cell lines. It induces degradation of Ikaros family zinc finger proteins 1, 2, and 3 (IKZF1/2/3) and casein kinase 1 alpha (CK1α) with nanomolar potency via a Cullin-cereblon (CRBN) dependent pathway. Compared to lenalidomide and pomalidomide, MGD-28 achieves deeper, faster, and more potent degradation of these neosubstrates. Additionally, MGD-28 exhibits broad antiproliferative activity in multiple solid malignancies and shows preferential cytotoxicity toward multiple myeloma patient-derived cells at various disease stages.
DC67413 MRT-23227
DC67412 MRT-3486 MRT-3486 (Compound 5) is a cereblon-based NEK7 molecular glue degrader. MRT-3486 can be used for autoinflammatory diseases research.
DC67411 MRT-7612
DC67410 MRT-10350
DC67407 IKZF1-degrader-1 IKZF1-degrader-1 (Compound 9-B) is a highly potent molecular glue that achieves sub-nanomolar degradation of IKZF1 (DC50 = 0.134 nM), demonstrating significant therapeutic potential for targeting IKZF1-dependent malignancies.
X